Pfizer (PFE) Stock Price, Chart, Company Profile & AI Analysis

Key Takeaways

• Pfizer (PFE) closed at $30.52 on October 30, 2026, up roughly 7% over the trailing 30 days and trading near a fresh 52-week high.
• The shares have climbed about 18–20% year to date, signaling renewed investor confidence in the company's post-pandemic turnaround.
• Recent catalysts include FDA approval of the TALZENNA plus XTANDI combination in an earlier prostate-cancer setting and positive Phase 3 data for ELREXFIO in multiple myeloma.
• Pfizer raised its full-year revenue guidance in August to a range of $60.5 billion to $62.5 billion while reiterating adjusted EPS guidance of $2.80 to $3.00.
• The company's cost-reduction program targets up to $6.7 billion in savings through 2029, and the stock carries a forward dividend yield near 5.8%.
• For additional detail on the company's Price Targets, Earnings, and Forecast, explore the dedicated analysis pages.
• Traders can also explore Trending AI Robots to see which automated strategies are currently active.

Current Market Snapshot

Pfizer shares have extended a steady recovery from their post-pandemic slump, rising about 7% over the trailing 30 days and reaching a new 52-week high in late October 2026. The move has been driven by a mix of pipeline momentum, disciplined cost management, and a higher dividend yield that continues to attract income-focused investors. While the stock trades at a modest multiple of estimated forward earnings, sell-side views remain divided, with firms such as Guggenheim and Jefferies maintaining Buy ratings while others, including Citi and UBS, hold more cautious stances. The broader healthcare sector's defensive characteristics have provided additional support as investors weigh a range of macroeconomic crosscurrents.

Pfizer (PFE) Business Overview and Competitive Position

Pfizer Inc. is one of the world's largest biopharmaceutical companies, discovering, developing, and commercializing medicines and vaccines across primary care, specialty care, and oncology. Its portfolio spans widely used treatments such as the blood thinner Eliquis, oncology therapies including Padcev, Lorbrena, and Talzenna, and an expanding pipeline in areas like multiple myeloma and metabolic disease. The company's scale, global distribution network, and research capabilities position it as a cornerstone of the global healthcare industry. Investors follow Pfizer closely for its ability to replace revenue from COVID-19 products, manage an approaching patent cliff on several blockbuster drugs, and generate a dependable dividend.

Recent Developments Driving PFE

Several verified developments have shaped sentiment around Pfizer in recent weeks. In late October, the FDA approved the TALZENNA plus XTANDI combination for an earlier metastatic prostate-cancer treatment setting, and the company reported that its ELREXFIO therapy met the primary endpoint in a Phase 3 trial for relapsed or refractory multiple myeloma. Pfizer also disclosed strong responses for a pediatric pneumonia vaccine candidate in a mid-stage study. On the financial side, management raised full-year revenue guidance in August and reiterated its adjusted earnings outlook while announcing plans to expand its cost-reduction program. Analyst activity has been mixed: Guggenheim reiterated a Buy rating with a $31 price target, Jefferies maintained a Buy with a higher target, while Citi and Bernstein held more neutral views. These pipeline wins and cost initiatives have underpinned the stock's climb toward 52-week highs.

Trending AI Robots

Tickeron's Trending AI Robots page highlights a curated selection of automated trading strategies that have recently demonstrated standout performance. Tickeron operates hundreds of AI-driven trading bots that collectively monitor and trade thousands of tickers, but only the top-performing and most relevant bots are featured in this section. Each robot differs in its underlying strategy, trading timeframe, and performance metrics, giving users a way to compare approaches ranging from short-term momentum to longer-horizon positioning. The page serves as a discovery tool rather than a guarantee of future results, and past performance does not ensure future outcomes. Investors and traders interested in automated, rules-based approaches can browse the current lineup of Trending AI Robots to see which strategies are attracting attention.

2026 Outlook and What Investors Should Watch

Looking ahead, investors are focused on Pfizer's upcoming quarterly earnings report and any updates to full-year guidance, particularly around adjusted EPS and revenue composition. The approaching patent expirations for Eliquis and Ibrance remain the central long-term concern, making pipeline execution a critical variable. Progress on the company's anti-obesity drug candidates acquired through the Metsera deal, further oncology data readouts, and additional regulatory approvals will be closely monitored. Cost-reduction execution and the sustainability of the near 5.8% dividend yield, which sits on a payout ratio of roughly 60%, are also key factors. Macroeconomic conditions, including interest-rate expectations and healthcare policy developments, could further influence sentiment. As always, clinical trial outcomes and competitive dynamics will play an outsized role in determining the stock's next move.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations